Immunic Inc. (IMUX), on Thursday, announced new data from its IMU-856 program, highlighting a dose-dependent increase in GLP-1 levels in patients from its Phase 1b trial for celiac disease.
The new data suggests IMU-856 may present a promising oral treatment option for weight management.
According to the trial findings, there was a significant increase in endogenous GLP-1 levels, up to 250 percent compared to placebo, in celiac disease patients.
In a 6-month preclinical in vivo study too, IMU-856 was found to reduce body weight and food intake by up to 40 percent.
IMU-856 targets SIRT6, a protein involved in intestinal barrier regeneration, and its effects on GLP-1 may activate enteroendocrine cells involved in regulating hunger and satiety.
The data from both clinical and preclinical studies suggest that IMU-856 could potentially be developed as an oral therapy for obesity, a market expected to exceed $170 billion by 2031.
Immunic's CEO, Daniel Vitt, Ph.D., emphasized the significance of these findings, noting that the oral, once-daily nature of IMU-856 could offer a unique alternative to injectable treatments for weight management.
IMUX closed Wednesday's (Feb.19 2025) trading at $1.05 down by 3.67%. In premarket trading Thursday the stock is up by 3.80% at $1.09.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.